Adjuvant and neoadjuvant vincristine, bleomycin, and methotrexate for inguinal metastases from squamous cell carcinoma of the penis

G. Pizzocaro, L. Piva

Research output: Contribution to journalArticle

Abstract

In a pilot study 12 patients with radically resected inguinal lymph node metastases from carcinoma of the penis and 5 patients with fixed inguinal nodes were treated with 12 weekly courses of vincristine, bleomycin and methotrexate (VBM). Only 1 of the 12 cases treated with adjuvant VBM relapsed after a median follow-up period of 42 months (range 18-102 months). Three partial responders to neoadjuvant VBM could have radical lymphadenectomy and they are alive disease-free 20, 27, 72 months after surgery. Two minimal responders could not have radical surgery and they died of the disease within one year.

Original languageEnglish
Pages (from-to)823-824
Number of pages2
JournalActa Oncologica
Volume27
Issue number6
DOIs
Publication statusPublished - 1988

Keywords

  • Bleomycin
  • Chemotherapy
  • Lymph node metastases
  • Methotrexate
  • Penile cancer
  • Vincristine

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Hematology

Fingerprint Dive into the research topics of 'Adjuvant and neoadjuvant vincristine, bleomycin, and methotrexate for inguinal metastases from squamous cell carcinoma of the penis'. Together they form a unique fingerprint.

  • Cite this